Comparison of MMP-3 levels in rheumatoid arthritis after treatment with tocilizumab or infliximab for 12 weeks

Modern Rheumatology

Volumn 21, Issue 6, 2011, Pages 710-714

  Yokoe, Isamu ^a   Nishio, Shinya ^a   Sato, Hiroshi ^a   Kobayashi, Hitomi ^a  

^a Itabashi Chuo Medical Center   (Japan)

Author keywords

Interleukin 6 (IL 6); Matrix metalloproteinase 3 (MMP 3); Tumor necrosis factor (TNF)

Indexed keywords

INFLIXIMAB; STROMELYSIN; TOCILIZUMAB;

ADULT; CLINICAL ARTICLE; DISEASE ACTIVITY; ENZYME ANALYSIS; FEMALE; HUMAN; MALE; PRIORITY JOURNAL; REVIEW; RHEUMATOID ARTHRITIS; STATISTICAL ANALYSIS; TREATMENT DURATION; TREATMENT OUTCOME;

ADULT; AGED; ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; FEMALE; HUMANS; MALE; MATRIX METALLOPROTEINASE 3; MIDDLE AGED;

EID: 84855678288     PISSN: 14397595     EISSN: 14397609     Source Type: Journal    
DOI: 10.1007/s10165-011-0474-z     Document Type: Review

References (11)

1. Suzuki M, Hashizume M, Yoshida H, Shiina M, Mihara M. IL-6 and IL-1 synergistically enhanced the production of MMPs from synovial cells by up-regulating IL-6 production and IL-1 receptor expression. Cytokine. 2010;51:178-83.
2. Koike R, Takeuchi T, Eguchi K, Miyasaka N. Update on the Japanese guidelines for the use of infliximab and etanercept in rheumatoid arthritis. Mod Rheumatol. 2007;17(6):451-8.
3. Gravallese EM, Darling JM, Ladd AL, Katz JN, Glimcher LH. In situ hybridization studies of stromelysin and collagenase messenger RNA expression in rheumatoid synovium. Arthritis Rheum. 1991;34:1076-84.
4. Hasty KA, Reife RA, Kang AH, Stuart JM. The role of stromelysin in the cartilage destruction that accompanies inflammatory arthritis. Arthritis Rheum. 1990;33:388-97. (Pubitemid 20109191)
5. Yamanaka H, Matsuda Y, Tanaka M, Sendo W, Nakajima H, Taniguchi A, et al. Serum matrix metalloproteinase 3 as a predictor of the degree of joint destruction during the six months after measurement, in patients with early rheumatoid arthritis. Arthritis Rheum. 2000;43:852-8.
6. Klimiuk PA, Sierakowski S, Chwiecko J. Serum interleukin 6 (IL-6A) concentration correlates with matrix metalloproteinases and their tissue inhibitors in rheumatoid arthritis. Pol Arch Med Wewn. 2003;109:119-23. (Pubitemid 36378241)
7. Funahashi K, Koyano S, Miura T, Hagiwara T, Okuda K, Matsubara T. Efficacy of tocilizumab and evaluation of clinical remission as determined by CDAI and MMP-3 level. Mod Rheumatol. 2009;19:507-12.
8. Shinozaki M, Inoue E, Nakajima A, Hara M, Tomatsu T, Kamatani N, et al. Elevation of serum matrix metalloproteinase-3 as a predictive marker for the long-term disability of rheumatoid arthritis patients in a prospective observational cohort IORRA. Mod Rheumatol. 2007;17:403-8. (Pubitemid 47593489)
9. Smolen JS, Beaulieu A, Rubbert-Roth A, Ramos-Remus C, Rovensky J, Alecock E, et al. Effect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis(OPTION study): A double-blind, placebo-controlled, randomised trial. Lancet. 2008;371:987-97. (Pubitemid 351392039)
10. Garnero P, Thompson E, Woodworth T, Smolen JS. Rapid and sustained improvement in bone and cartilage turnover markers with the anti-interleukin-6 receptor inhibitor tocilizumab plus methotrexate in rheumatoid arthritis patients with an inadequate response to methotrexate: Results from a substudy of the multicenter double-blind, placebo-controlled trial of tocilizumab in inadequate responders to methotrexate alone. Arthritis Rheum. 2010;62:33-43.
11. Maini RN, Taylor PC, Szechinski J, Pavelka K, Broll J, Balint G, et al. Double-blind randomized controlled clinical trial of theinterleukin-6 receptor antagonist, tocilizumab, in European patients with rheumatoid arthritis who had an incomplete response to methotrexate. Arthritis Rheum. 2006;54:2817-29. (Pubitemid 44497760)